rabeximod (ROB 803) / Cyxone - LARVOL DELTA

INVESTIGATING THE TARGET AND MODE OF ACTION OF THE NEW ANTI-RHEUMATIC DRUG RABEXIMOD (EWRR 2024) - No abstract available

Inflammation

Cyxone AB is carrying out a rights issue of shares for approximately SEK 36.3 million (Cision) - "The board of Cyxone AB...has today...decided to carry out a rights issue of a maximum of 213,296,902 shares for approximately SEK 36.3 million before issue costs (the 'Rights Issue'). In connection with the Rights Issue, the Company has received subscription obligations and guarantee commitments of approximately SEK 20 million from persons in the Company's management and board of directors as well as external investors corresponding to approximately 55 percent of the Rights Issue. The issue proceeds from the Rights Issue are primarily intended to be used to finance further clinical development for the programs with Rabeximod and T20K. Notice of the extraordinary general meeting will be published through a separate press release."

Financing • Acute Respiratory Distress Syndrome • CNS Disorders • Immunology • Multiple Sclerosis • Rheumatoid Arthritis

MODE OF ACTION AND TARGET INVESTIGATION OF THE NEW ANTI-RHEUMATIC DRUG RABEXIMOD. (EULAR 2023) - "Moreover, in a phase IIa clinical trial a significantly higher clinical efficacy of RBM + Methotrexate versus Methotrexate alone has also been confirmed. Finally, after 24 hours, MDMs treated with RBM developed an altered morphology independently of the frequency of treatment exposure and the stage of inflammation. Conclusion Overall, our data suggest that RBM acts predominantly on monocytes/macrophages and can inhibit the production of pro-inflammatory molecules playing a crucial role in RA."

Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CSF1 • IL6 • SPP1 • TLR2 • TLR4

"Cyxone receives patent approval from the US for the salt forms of the compound rabeximod https://t.co/pttJq5ySsW" (@CisionNews)

Investigating the target and mode of action of the new antirheumatic drug Rabeximod. (EWRR 2023) - No abstract available

"Cyxone gör betydande framsteg i tillverkningsprocessen för Rabeximod https://t.co/SNhtQa0ga4" (@CisionNews)

"Cyxone makes significant progress in the manufacturing process for Rabeximod https://t.co/zmPagMt978" (@CisionNews)

[VIRTUAL] THE MYB-TYK2 GENE FUSION INDUCES B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA IN IN VITRO AND IN VIVO MODELS AND CAN BE EFFECTIVELY TARGETED BY THE DUAL SYK/JAK INHIBITOR, CERDULATINIB. (EHA 2020) - P1/2 | "Immunophenotypic analysis demonstrated arrest at pro/pre- B cell stage (CD45R/B220+, CD43­+, CD19+, CD24+, BP-1+ and IgM+/-)...In addition, cerdulatinib was identified as a novel drug against MYB-TYK2 altered disease in vitro and in vivo to aid development of targeted therapeutic approaches against this aggressive ALL subtype. This inhibitor may also be effective against other genomic alterations that result in aberrant JAK-STAT signalling."

Preclinical • Acute Lymphocytic Leukemia • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • CD24 • CD43 • SYK

"Cyxone gör framsteg med patentportföljen för Rabeximod https://t.co/m6bhCNXm8J" (@CisionNews)

"Cyxone advances the patent portfolio for Rabeximod https://t.co/1K5zacjsIy" (@CisionNews)

A study to evaluate the possible side and the efficacy of orally administered Rabeximod when taken in combination with methotrexate compared with Methotrexate only in patients with active, moderate to severe rheumatoid arthritis with inadequate response to methotrexate (clinicaltrialsregister.eu) - P2 | N=160 | Ongoing | Sponsor: Cyxone AB

Combination therapy • New P2 trial • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Rheumatoid Arthritis • Rheumatology • CRP

"Cyxone reports publication of four patent applications pertaining to its drug candidate Rabeximod https://t.co/XCi29YsPJB" (@CisionNews)

A Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety and Efficacy of Rabeximod Compared to Standard of Care in Patients With Moderate Coronavirus Disease (COVID-19) (clinicaltrialsregister.eu) - P2; N=300; Ongoing; Sponsor: Cyxone AB

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

"BioStock: Cyxones Covid-19-studie med Rabeximod inledd i Europa https://t.co/dPpDvpFJpR" (@CisionNews)

Infectious Disease • Novel Coronavirus Disease

Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod (PRNewswire) - "Cyxone (publ.) announced today that the first patient has been screened in the Phase 2 clinical trial of Rabeximod in Covid-19. The trial will evaluate the efficacy and safety of oral treatment with Rabeximod to prevent disease progression in hospitalized Covid-19 patients and shorten the time to recovery. The study will include 300 patients at clinical centers in Poland, Slovakia and up to three additional countries in Europe. Cyxone expects to announce preliminary results in the third quarter of 2021....The company has also filed for regulatory approval in Slovakia, Hungary and Ukraine, and is preparing for submissions in additional countries."

P2 data • Trial status • Infectious Disease • Novel Coronavirus Disease

Five Treatment Strategies to Suppress Donor Specific Antibodies: Highlights from a Decade of Research Experience in a Mouse Model of Allo-Sensitization (ISHLT 2020) - "Drugs tested include (1) anti-CD20 (B-cell depletion); (2) Ibrutinib (Bruton's tyrosine kinase inhibitor, BTKi); (3) Tofacitinib (Janus Kinase Inhibitor, JAKi); (4) anti-IL6 receptor and anti-IL6 (interleukin 6 pathway blockage) and (5) CTLA4Ig (abatacept, CD28 pathway manipulation)...Administration of anti-CD20 significantly reduced levels of DSA IgG (p90% B220+/CD5− B-cells...A combined therapy using anti-CD20, CTLA4Ig and anti-IL6r resulted in strongest DSA reduction in both de novo and recall responses. Conclusion Our data demonstrate that a maximal suppression can be achieved by combined therapies targeting multiple pathways critical of CD4 T-cell activation, B/plasma cell activation and antibody production."

Preclinical • Antibody-mediated Rejection • Transplantation

Cyxone has filed an IND in the US with Rabeximod following positive feed-back from pre-IND meeting with the FDA (PRNewswire) - "Cyxone...announced today that the company has filed an Investigational New Drug (IND) application...pertaining to its drug candidate Rabeximod. The application follows on a productive pre-IND meeting with the authority where valuable advice was received on...European Phase 2 clinical study in moderate Covid-19....The IND covers the development of Rabeximod in Covid-19 and other indications, such as rheumatoid arthritis...The authority's advice has been incorporated in the study protocol for the clinical study of Rabeximod in Covid-19, which is expected to be initiated shortly in Europe."

IND • Infectious Disease • Novel Coronavirus Disease • Rheumatoid Arthritis

Cyxone receives regulatory approval to initiate a clinical Phase 2 study with Rabeximod in Covid-19 patients (PRNewswire) - "Cyxone (publ.) announced today it has received approval from the regulatory authority and the ethics committee in Poland to initiate a Phase 2 clinical trial with Rabeximod in moderate Covid-19 patients....Company has filed for regulatory approval in Slovakia, and is preparing for submissions in additional countries....Cyxone aims to present preliminary study data in Q3 2021....Given a positive study outcome, the company plans to enter into a strategic partnership with a global pharmaceutical company in order to further progress the development and commercialization..."

New P2 trial • Infectious Disease • Novel Coronavirus Disease

[VIRTUAL] An Inducible Model of Early Lupus Nephritis (KIDNEY WEEK 2020) - "Topical treatment with toll like receptor-7(TLR7) agonist Imiquimod(IMQ) for 8 weeks has been shown to induce glomerulonephritis(GN), significant weight loss and mortality... Treated mice had increased numbers of activated splenic CD4 and CD8 T cells(CD44hiCD62Llow,P<0.001), Tregs(CD4+CD25+FOXP3+,P<0.01) and activated B cells(B220+CD19+CD86+CD69+,P<0.001)... This study characterises the IMQ model of LN revealing CD44hi T cell activation and TEM evidence of immune deposits reminiscent of human class II lupus. Treatment for 5 weeks is well tolerated without overt renal failure and creates a model for studying the early pathways involved in immune complex GN and associated therapeutic targets."

Complement-mediated Rare Disorders • Fibrosis • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • CD19 • CD44 • CD8 • FOXP3 • IL2RA

PKN1 kinase-negative knock-in mice develop splenomegaly and leukopenia at advanced age without obvious autoimmune-like phenotypes. (PubMed, Sci Rep) - "Additionally, flow cytometry revealed increased numbers in B220, CD3, Gr1 and CD193 leukocytes in the spleen of aged PKN1[T778A] mice, whereas the number of lymphocytes, neutrophils, eosinophils, and monocytes was reduced in the peripheral blood, suggesting an advanced impairment of leukocyte trafficking with age. Moreover, aged PKN1[T778A] mice showed no obvious GC formation nor autoimmune-like phenotypes, such as glomerulonephritis or increased anti-dsDNA antibody titer, in peripheral blood. Our results showing phenotypic differences between aged Pkn1-KO and PKN1[T778A] mice may provide insight into the importance of PKN1-specific kinase-independent functions in vivo."

Journal • Preclinical • Glomerulonephritis • Hematological Disorders • Hematological Malignancies • Immunology • Leukopenia • Lupus Nephritis • Lymphoma • Nephrology • Oncology • Renal Disease

"Cyxone rapporterar positivt utfall från regulatoriska toxikologistudier av Rabeximod https://t.co/oBWjiqIYmN" (@CisionNews)

Oligodendrocyte-specific deletion of FGFR2 ameliorates MOG -induced EAE through ERK and Akt signalling. (PubMed, Brain Pathol) - "Oligodendrocyte-specific knockout of FGFR2 (Fgfr2 ) was achieved by application of tamoxifen; EAE was induced using the MOG peptide...The number of CD3(+) T cells, Mac3(+) cells and B220(+) B cells was less in demyelinated lesions of Fgfr2  mice...These data suggest that cell-specific deletion of FGFR2 in oligodendrocytes has anti-inflammatory and neuroprotective effects accompanied by changes in FGF/FGFR dependent signalling, inflammatory cytokines and expression of remyelination inhibitors. Thus, FGFRs in oligodendrocytes may represent potential targets for the treatment of inflammatory and demyelinating diseases including MS."

Journal • CNS Disorders • Immunology • Inflammation • Multiple Sclerosis • Solid Tumor • FGF2 • FGFR1 • FGFR2

Temporin L-derived peptide as a regulator of the acute inflammatory response in zymosan-induced peritonitis. (PubMed, Biomed Pharmacother) - "More importantly, flow cytometry analysis highlighted a selective modulation of infiltrating inflammatory monocytes (defined as B220/GR1-F480/CD115) after peptide 2 treatment. Our results and presented models offer the possibility to test, in a preclinical setting, the potential of temporin analogues as anti-inflammatory agents."

Journal • Immune Modulation • Immunology • Inflammation

NCM 1921, a Mixture of Several Ingredients, Including Fatty Acids and Choline, Attenuates Atopic Dermatitis in 1-Chloro-2,4-Dinitrobenzene-Treated NC/Nga Mice. (PubMed, Nutrients) - "NCM 1921 normalized the total cell number in dorsal skin tissue, the axillary lymph node, and spleen following DNCB exposure and reduced the number of CD23+/B220+ cells in the axillary lymph node and CD3+ cells in dorsal skin tissue...Immunohistofluorescence staining showed that NCM 1921 treatment significantly increased claudin1, filaggrin, and Sirt1 protein expressions in AD skin lesions. These results suggest that NCM 1921 could be a valuable remedy for the treatment of AD."

Journal • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

"Cyxone har lösningen på det här. Rabeximod for the win." (@redhookhotw)